corneal vascularization causes & management review
TRANSCRIPT
![Page 1: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/1.jpg)
Corneal neovascularization-pattern,causes and
management
Dr. pramod bhumarkarRSO Ophthalmology
G.M.H, S.S.M.C REWA
![Page 2: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/2.jpg)
• Cornea is a immunologically privileged organ because of its non vascular nature
• Avascularity helps in maintaining corneal transparency
• Essential for good visual acuity
![Page 3: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/3.jpg)
VASCULOGENESIS & ANGIOGENESIS
New blood vessel formation occurs by two mechanism;
1.Vasculogenesis: by differentiation of angioblasts & endothelial cell
2.Angiogenesis: from preexisting microvasculature there is balance between endogenous stimulators & inhibitors any imbalance result in vascularisation
![Page 4: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/4.jpg)
WHY NEOVASCULARIZATION OCCUR
• Corneal neovascularisation is the condition in which excessive in- growth of blood vessels takes place, from the limbal vascular plexus into the cornea. It is caused due to less intake of oxygen from the air
![Page 5: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/5.jpg)
Inflammatory & hypoxic disruption of balanced corneal immune system
In response the body attempts to provide necessary nutrients and oxygen to the deprived corneal tissues by the creation of new blood vessels.
![Page 6: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/6.jpg)
During the early stages, this abnormal growth of blood vessels may produce no signs at all, or it may cause a variety of symptoms, including eye pain and excessive tearing, light sensitivity, redness, intolerance to contact lenses, and decreased vision
![Page 7: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/7.jpg)
Pathophysiology• When compactness of corneal tissue is
lossened by either mechanically irritating the limbal sulcus or by creating corneal hypoxia, which leads to limbal inflammation, epithelial erosion, or hypertrophy, and, hence, angiogenic mediator release.
![Page 8: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/8.jpg)
ANGIOGENESIS STIMULATOR
• Vascular endothelial growth factor• Fibroblast growth factor• Insulin like growth factor• Integrins • Platelets derived growth factor• Transforming growth factor • Tumor necrosis factor• Matrix metalloproteinase
![Page 9: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/9.jpg)
Common causes of Angiogenesis
• Disease leading to inflammation herpetic keratitis• Disease leading to Hypoxia
contact lenses• Disease with inherited
Aniridia
acquired
chemical cautery
![Page 10: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/10.jpg)
Causes of Corneal Neovascularisation;
The causes of corneal neovascularisation includes:
Any trauma to eyes Wear and tear in contact lenses Immunological disease Burn to eye due to some chemical
![Page 11: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/11.jpg)
• Angiogenic factors released by local epithelial cells, keratocytes, and infiltrating leukocytes(eg macrophages, neutrophils)
• stimulate localized enzymatic degradation of the basement membrane of perilimbal vessels at the apex of a vascular loop. Vascular endothelial cells migrate and proliferate to form new blood vessels
![Page 12: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/12.jpg)
Types Superficial
deep pannus
superficial
deep pannus
![Page 13: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/13.jpg)
SUPERFICIAL
Vessels arrange in arborizing pattern& below epithelial layer & can be traced with conjuctival vessel
• trachoma• phytenular conjuntivitis • superficial corneal ulcer• rosacea keratitis
![Page 14: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/14.jpg)
DEEP Derived by anterior cilliary artery & lie in
corneal stroma usually straight & not anastomosing
continuity can not be traced beyond limbus
• Interstitial keratitis• deciform keratitis• deep corneal ulcer• chemical burn• sclerosing keratitis• graft rejection
![Page 15: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/15.jpg)
• Pannus
extensive superficial vascularisation with cellular infiltration
1 progressive
2 regressive
![Page 16: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/16.jpg)
ADVANTAGES OF NEOVASCULARISATION
• Transport humoral & cellular elements of immunological defense & raw material
• Repair & regeneration • Carry antibiotic & drugs to sites of infection • Eliminates toxic substance
![Page 17: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/17.jpg)
Disadvantages of neovascularisation
• Persist after healing process is completed• Interfere with corneal transparency• Lymphatic establishment which disrupt
immune privilege• Sensitization to other antigen• Graft rejection & failure in keratoplasty
![Page 18: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/18.jpg)
Complications New blood vessels are known to be leaky and occasionally deposit opaque material (eg, lipids, cholesterol) in the normally transparent cornea.If the vessels extend to the point where such deposits occur in the visual axis, they can compromise vision.
•Corneal edema•Lipid keratopathy•Corneal opacity•Graft rejection In keratoplasty• Intrastromal /subepithelial bleeding• Blindness
![Page 19: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/19.jpg)
Why need to treat neovascularisation
• Corneal neovascularisation (NV) represents the main risk factor for immune rejection after corneal transplantation.
• The healthy cornea devoid of blood vessels is said to be immune-privileged and when corneal grafts are placed into an avascular recipient corneal bed (low-risk keratoplasty) the two-year survival approaches 90% under treatment with a topical corticosteroid.
• The survival rates of corneal grafts placed onto vascularized recipient beds (high-risk keratoplasty) decrease significantly to below 50%.Additionally, even in the low risk setting, mild angiogenesis develops after keratoplasty and increases the risk for immune rejection.
• For this reason, aggressive treatment of neovascularization may be necessary prior to corneal transplant surgery to ensure a lower chance of graft rejection.
![Page 20: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/20.jpg)
Prophylaxis Dietary Isoflavonoidsand Flavonoids
(Genistein, Fisetin and Luteolin) were dissolved in a microemulsion to increase bioavailability and applied topically in concentrations between0.5 and 1 ng ml.
Fisetinhad the strongest effect followed by Genistein and Luteolin. Riboflavin-UVA Ribonuclease Inhibitor Regulates Neovascularization by
Human Angiogenin Human angiogenin (ANG) is a homologue of bovine pancreatic ribonuclease (RNase A) that induces neovascularization
RGN-259 is a sterile eye drop formulation of thymosin beta 4 \Tβ4
REFERENCE
Fotsis et al.Genistein,a dietary-derived inhibitor of in vitro angiogenesis. Journal of Refractive Surgery Vol. 25 No. 9 September 2009
![Page 21: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/21.jpg)
DEXPANTHENOL
• The topical use of dexpanthenol stable alcoholic analog of pantothenic acid
• Activation of fibroblast proliferation, which is of relevance in wound healing.
• Accelerated re-epithelization in wound healing
• Anti-inflammatory effect
![Page 22: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/22.jpg)
TREATMENTMEDICAL
Treat the cause first
Other mode of treatment are
• Lubricating• NSAIDS • Topical corticosteriod• Antiangiogenic agent
![Page 23: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/23.jpg)
ANTIANGIOGENIC AGENT
• Angiostatic steriods• Vascular endothelial growth factor inhibitor• Protein kinase c inhibitor• Matrix metalloprotinase inhibitor• Cox-2 inhibitor• Antioxidants• Thalidomide• Dietary derived inhibitor• Ion channel blockers
![Page 24: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/24.jpg)
• Angiostatic steriod- It inhibits macrophages that release growth factor, prevent intercellular adhesion leading to leukocyte adhesion & transmigration.
• They can slow the progression of neovascularization ,but cannot stabilize or reverse the process
![Page 25: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/25.jpg)
Vasculoendothelial growth factor inhibitor;
VEGF was expressed by epithelial cells, endothelial cells, vascular endothelial cells of limbal vessels and of newly formed vessels in the stroma, and weakly by keratocytes.
Drug which are under trial to inhibits VEGF
a Bevacizumab
b Pegaptanib sodium
c Ranibizumab; anti VEGF monoclonal antibodies
![Page 26: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/26.jpg)
COX-2 inhibitor;Nepafenac;topical readily penetrates cornea &
metabolized to amfenac, a potent cox-1 & cox-2 inhibitor,antinflammatory action
Antioxidants :reactive oxygen species stimulate VEGF production. Vitamin-E inhibit reactive oxygen species& subsequent event also inhibit pericyte loss & play a role in decreasing microvascular change & angiogenesis
![Page 27: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/27.jpg)
• Dietary derived inhibitor– genistein a synthetic isoflavonoid compound
inhibitor of endothelial cell production & angiogenesis
• ION CHANNEL BLOCKER:• Amiloride inhibits capillary morphogenesis
completely & block endothelial cell proliferation
![Page 28: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/28.jpg)
Topical/Subconjunctival Injection of Bevacizumab (Avastin) for the Treatment
of Corneal Neovascularization
• Bevacizumab (trade name Avastin, Genentech/Roche) is a humanized monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF).
• Drug: Bevacizumab Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc
![Page 29: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/29.jpg)
• Destafeno et al* reported the use of a topical formulation of bevacizumab, a humanized monoclonal antibody to VEGF, in 2 patients with significant corneal NV.
• The Duke University Hospital assisted with the topical formulation of bevacizumab established by mixing the commercially available bevacizumab (Avastin 400 mg, 25mg/mL) with 0.5% (5 mg/mL) stock benzalkonium chloride (BAK) and sterile saline 0.9%. The final formulation yielded a concentration of bevacizumab 10 mg/mL (1.0%) in 0.01% BAK with a pH of 6.2. The solution was dispensed in 5 mL vials.
*Destafeno et al. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol.2007;125:834–36.
![Page 30: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/30.jpg)
• Topical anti-VEGF therapy could play an important role in improving graft survival in patients who have preexisting corneal NV or NV develops after penetrating keratoplasty .
• corneal NV associated with contact lens wear. • The reduction or elimination of corneal NV could therefore
allow for corneal transplantation or refractive surgery in those patients who were previously considered high risk and had contraindications to surgery.
• The use of subconjunctival bevacizumab in human studies has shown a positive effect on regression of corneal neovascularisation
![Page 31: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/31.jpg)
• But because of its cost & lack of availablity in our institution we are not using
• The cost of preparation for this topical solution was about $500/5ml vial
![Page 32: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/32.jpg)
Effect of topical amiloride• Potassium sparing diuretics, competitive inhibitor of
urokinase plasminogen activator (uPA)• uPA is serine protease degrade basement membrane &
permits endothelial invasion• Amiloride inhibit the conversion of plasminogen to
plasmin& prevent degradation • Avery et al* studied effect of systemic amiloride in rabbit
eyes & observed 55% regression• Sood et al** reported topical use accelerate healing &
delay neovascularisation in mechanically produced ulcer in rabbits
*Avery et al arch ophthalmology 1990;108;1474-6
**Sood et-al methods find exp clin pharmacol. 1999,21;491-7
![Page 33: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/33.jpg)
o A clinical trial on human eyes was done in 2001 in freshly operated case of pterygium
o Topical amiloride (0.04)significantly prevented as well as regressed active neovascularization in qid dosage
o No effect on long standing cases of neovascularisationo Topical prepared by dissolving amiloride powder in
normal saline filling in tinted glass bottles which were autoclaved & finally stored in refrigerator
![Page 34: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/34.jpg)
• SURGICAL
1 Noninvasive; LASER
2 Invasive;PERITOMYDIATHERMY
![Page 35: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/35.jpg)
LASER PHOTOCOAGULATION
• Used to treat vascularization in lipid keratopathy & graft rejection
• Cherry & garner* first reported the use of argon laser in human
• Marsh & coworkers **treated lipid keratopathy patient with minimum followup period of 9 month
*Cherry PMH et al. Argon laser treatment of corneal neovascularisation. Br J ophthalmology. 1976;60(6);464-472
**Marsh et al,Bjophthalmology , treatment of lipid keratopathy with argon laser 1998 72.900-4
![Page 36: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/36.jpg)
• Nirankari & Baer* treated patient of deep vascularization &reported good result with regard to reversal of active graft rejection
*NirankariVSBaer et al, CALP in penetrating keratoplasty 1986; 93 ,1304-1306
![Page 37: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/37.jpg)
• A sharma* demonstrates that corneal laser photocoagulation is a safe and effective method of decreasing the area of corneal vascularisation in quiescent eyes with vascularised corneal opacities, the procedure decreases the area of vascularisation, area of corneal opacity, and improves vision in a significant number of patients with lipid keratopathy
*Sharma A et al, Frequency doubled Nd :YAG (532 nm) laser photocoagulation
in corneal vascularisation : efficacy and time sequenced changes. Indian J Ophthalmol 2001;49;235
![Page 38: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/38.jpg)
LASER PHOTOCOAGULATION
• Laser photocoagulation was done using frequency-doubled Nd: YAG (532 nm) laser and Abraham contact lens.
• Laser parameters used were 120-480 mw
of power, 50-150 mm spot size and 0.05 second pulse duration.
![Page 39: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/39.jpg)
• The patients were followed up at one week, one month, two months and three months after the last laser treatment.
• The effect on laser-treated vessels was recorded as complete occlusion, partial occlusion, recanalisation and appearance of shunt vessels on slitlamp biomicroscopy
![Page 40: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/40.jpg)
complications • Bleeding into lipid keratopathy,• corneal thinning• Iris atrophy• crystalline deposits on iris • peaking of pupil
![Page 41: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/41.jpg)
DIATHERMY• single-armed needle attached to a 10–0
monofilament black nylon suture was used with a microsurgical needle holder
• The needle was inserted close to the limbus, parallel to and at same depth as the blood vessel(s) to be occluded.
![Page 42: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/42.jpg)
• A unipolar diathermy unit was set to its lowest setting (0.5–1 mA). (Any unipolar diathermy unit with the capability of low power setting could be used.)
• In the coagulating mode, the diathermy probe was brought into contact with the corneal
needle, and contact was maintained until mild blanching of the corneal stroma occurred (usually a second or less).
• Each feeder vessel was treated individually.
![Page 43: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/43.jpg)
• At each follow-up visit, patency and recanalization of vessels, visual acuity, intraocular pressure, and any other complications were noted.
• Patency of vessels was assessed using slit-lamp biomicroscope examination by observing the flow of red blood cells through corneal vessels.
![Page 44: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/44.jpg)
• Side effects– Transient whitening of the cornea was
observed in the stroma , this occurred in all patients treated with FND and persisted for 24 to 48 hours, with complete resolution.
![Page 45: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/45.jpg)
PERITOMY
• Performed under local anaesthesia. Xylocaine 4% was used as surface anaesthesia and Xylocaine 2% was infiltrated subconjunctivally in the selected area.
• A 3 mm broad strip of conjunctiva extending on either side 1 mm beyond the extent of the ulcer was removed from the limbus.
The underlying bloodvessels were destroyed thoroughly by heat cautery.
![Page 46: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/46.jpg)
•Care was taken to avoid excessive cautery causing charring of sclera.
•An antibiotic eye drop was applied and the eye was patched for 3-4 days. The antibiotic eye drop was continued for further 10 days.
•The patients were subsequently followed up once a week for 4 weeks and once a month thereafter. The average follow up period till now is 6 months.
![Page 47: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/47.jpg)
THANKS YOU
![Page 48: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/48.jpg)
REFERENCE• DeStafeno JJ, Kim T (2007) Topical bevacizumab therapy for
corneal neovascularization. Arch Ophthalmol 125:834–836• Erdurmus M, Totan Y (2007) Subconjunctival bevacizumab for
corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245:1577–1579
• Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chévez-Barrios P (2007) Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91:804–807
• Barros LF, Belfort-Jr R (2007) The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 79:389–394
![Page 49: Corneal Vascularization Causes & Management Review](https://reader034.vdocument.in/reader034/viewer/2022050712/5526fd0c5503460e368b4614/html5/thumbnails/49.jpg)
REFERENCE• Baer JC, Foster CS. Corneal laser photocoagulation of treatment of
neovascularisation. Ophthalmology 1992;9:173-79. • Nirankari VS. Laser photocoagulation for corneal stromal vascularisation. Tr
Am Ophthalmol 1992;9 • Cherry PMH, Faulkner JD, Shaver RP, Wise JB, Witter SL. Argon laser
treatment of corneal neovascularisation. Ann Ophthalmol 1973;5:911-20.
• Reed JW, Fromer C, Klineworth GK. Induced corneal vascularisation remission with argon laser therapy. Arch Ophthalmol 1975;93:1017-19.
• Goto S. Q switched Nd: YAG laser treatment for corneal neovascularisation. Jpn Ophthalmol 1992;36:291-300.
• Sharma A, Samal A, Narang S, Gutpa A, Ram J, Gupta A. Frequency doubled Nd :YAG (532 nm) laser photocoagulation in corneal vascularisation : efficacy and time sequenced changes. Indian J Ophthalmol 2001;49:235